Wednesday, 13 Dec 2017

Biologic/Novel Rx

Datesort ascending Type Title Save
15 May 2017 Social In #Crohns disease Tofacitinib fails to maintain remission in randomized W/D, results of 2 Placebo RCT. https://t.co/9KXQxdq9kw
12 May 2017 Social Uptacitinib (Abbvie Jak 1 inhibitor) shows efficacy in Crohns dz (CELESTE RCTl) w/ remission rates at 6 &24 mg bid https://t.co/ssZT2D6nWk
10 May 2017 Social Responses to Orencia may be dependent on baseline memory B cells (CD38+ CD27+) https://t.co/zro040Y54W
07 May 2017 Social FDA has accepted Sanofi/Regenerons resubmitted BLA for Sarilumab (IL-6 inhib) for RA w/ PFUFA action date 5/22/17 https://t.co/F9txx9QwLz
05 May 2017 Social Japan Study shows 8mg IV Actemra can be escalated to q3 wks IV or reduced to q5 wks IV according to q4wk response https://t.co/rLn6aJowry
04 May 2017 News Tofacitinib Effective in Ulcerative Colitis
04 May 2017 Social Pfizer submitted tofacitinib NDA to FDA for psoriatic arthritis. FDA prev denied the NDA for psoriasis w/ CR letter. https://t.co/bDmnc8QF3c
04 May 2017 Social Fostamatinib (Tavalisse) Syk inhib failed in RA, has been studied in ITP, new NDA for ITP submitted to FDA by Rigel. https://t.co/Nwull2hiB3
01 May 2017 Social OPT 1&2 RCT show Tofacitinib to improve nail psoriasis: NAPSI75 scores PBO 6.8%, Tofa 5mg 16.9%, 10 mg 28.1% bid https://t.co/YCtVbkF5Cf
29 Apr 2017 Social RT @NYTHealth: You asked: What is it about so many medications that causes dryness in the mouth? Here's a short explanation. https://t.co/B…
26 Apr 2017 Social Sandoz biosimilars of Enbrel and Rituxan were recommened by CHMP for approval/use in the EU. EMA decision awaited https://t.co/zLrPlnKsZF
21 Apr 2017 Social Small study of 13 alopecia pts (2 totalis, 7universalis); Xeljanz Rx 7/13 had >50% regrowth w/in 9 mos, 2 d/c https://t.co/w5OxVvdIvQ
18 Apr 2017 Social How will new BIOSIMILAR biologic drugs affect PATIENTS - Make Your views count in a survey; Patients vote HERE>> https://t.co/Q0mXqI5rnc
17 Apr 2017 News Anti-IL-23 Therapy Effective in Crohn's Disease
16 Apr 2017 Social When BIOSIMILARS become available will PATIENTS use/accept them or switch to them? Survey for Patients, vote now>> https://t.co/V3yVcfakyd
15 Apr 2017 Social Will there be issues with BIOSIMILAR Safety, Switching or Cost? Patient survey: please vote 5 quick questions here https://t.co/LEcq7jSOzy
15 Apr 2017 Social Patient survey on BIOSIMILARs. Vote here if you have #RA, #PsA, #PSO, #AS, #IBD >> https://t.co/7eYnjPGCIH
14 Apr 2017 Social Biosimilars are suppose to save alot of money, but for whom? Patients can vote on this question and more @ RheumNow https://t.co/VWkfaC6RuN
14 Apr 2017 Social How will new BIOSIMILAR biologic drugs affect PATIENTS - Make Your views count in a Patient survey; vote at>> https://t.co/ZhM9MiDCd7
14 Apr 2017 News FDA Delays Baricitinib Decision